Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 10/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280581 | 1.00 | MEN1 (0.43) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| SCHEMBL985369 | 0.84 | MEN1 (0.46) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| SCHEMBL985368 | 0.84 | MEN1 (0.46) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL985144 | 0.82 | GNAI3 (0.45) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL985143 | 0.82 | GNAI3 (0.45) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| SCHEMBL3059596 | 0.82 | MEN1 (0.47) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL17796058 | 0.80 | GNAI3 (0.46) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| SCHEMBL15155982 | 0.76 | EPHX2 (0.56) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| SCHEMBL25933055 | 0.76 | MEN1 (0.42) | MEN1ALDH1A1KMT2AGNAI3GNAO1 | |
| SCHEMBL25930930 | 0.76 | MEN1 (0.42) | MEN1ALDH1A1KMT2AGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| EP-2417138-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Schering Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MEN1 1398/4885ALDH1A1 3479/4885KMT2A 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.